³»¿ë |
½Å¾à°³¹ß °úÁ¤¿¡¼ PBPK ¸ðµ¨¸µ/½Ã¹Ä·¹À̼ÇÀ» ±â¹ÝÀ¸·Î ÇÏ´Â IVIVEÀÇ ¼¼°èÀû ´ëÇ¥ ÇÁ·Î±×·¥ÀÎ Simcyp ¿öÅ©¼¥À» Çѱ¹¿¡¼ óÀ½ °³ÃÖ ÇÒ ¿¹Á¤ ÀÔ´Ï´Ù.
±×µ¿¾È ¾Æ½Ã¾Æ¿¡¼´Â ÀϺ»°ú Áß±¹¿¡¼ °³ÃֵǾúÁö¸¸, ¾ð¾îÀû Áö¿ø µîÀÇ Àå·¡·Î, ¹Ì±¹À̳ª À¯·´ µîÀ¸·Î Âü¼®À» Çϰí ÀÖ´Â ±¹³» ½Å¾à°³¹ß °ü·Ã ¿¬±¸ÀÚ ºÐµé²² ÁÁÀº ±âȸ°¡ µÉ °ÍÀ¸·Î »ý°¢ ÇÕ´Ï´Ù.
À̹ø¿¡´Â Ưº°È÷ ¿öÅ©¼¥ ¸¶Áö¸· ³¯¿¡´Â "Model Informed Precision Dosing" À̶ó´Â ÁÖÁ¦·Î ±¹³»¿Ü Àü¹®°¡µéÀ» ¸ð½Ã°í º°µµÀÇ ½ÉÆ÷Áö¾öÀ» °°ÀÌ Áغñ Çϰí ÀÖ½À´Ï´Ù. Âü¼®ÀÚ´Â ±¹³»¿Ü ÇÕÃļ 50¸íÀ» ¼±Âø¼øÀ¸·Î Á¦ÇÑ Çϰí ÀÖÀ¸´Ï, °ü½É ÀÖÀ¸½Å ºÐµé²²¼´Â Âü°í ÇϽñ⠹ٶø´Ï´Ù. Ȥ½Ã, ÀÌ¿Í °ü·Ã ¹®ÀÇ »çÇ× ÀÖÀ¸¸é ÀÎÁ¦ÀÇ´ë ¾à¸®Çб³½Ç ½Å Àç±¹ ±³¼ö ¿¬±¸½Ç (051-890-6709)·Î ÀüÈ ¿¬¶ô Áֽñ⠹ٶø´Ï´Ù.
- ÀϽà : 2017³â 12¿ù 11ÀÏ(¿ù) - 15ÀÏ(±Ý), 5Àϰ£
- Àå¼Ò : ºÎ»ê ÆÄ¶ó´ÙÀ̽ºÈ£ÅÚ
- EARLY REGISTRATION : 2017³â 06¿ù 09ÀÏ
- ÇÁ·Î±×·¥
"Model-informed drug development : Incorporating population variability into mechanistic prediction of PK and modelling PK-PD"
• Metabolic drug clearance (CL)
• Metabolic drug-drug interactions (DDIs)
• Gut first-pass metabolism
• Oral drug absorption incorporating food effects and the impact of dosage form
• Effect of transporters and enterohepatic recirculation on kinetics and DDIs
• Drug distribution to different organs |
|